Incyte Co. Expected to Earn Q1 2018 Earnings of ($0.33) Per Share (INCY)

Incyte Co. (NASDAQ:INCY) – Analysts at Leerink Swann issued their Q1 2018 EPS estimates for shares of Incyte in a research note issued on Friday. Leerink Swann analyst M. Schmidt expects that the biopharmaceutical company will earn ($0.33) per share for the quarter. Leerink Swann also issued estimates for Incyte’s Q2 2018 earnings at $0.03 EPS, Q4 2018 earnings at ($0.12) EPS and FY2020 earnings at $1.69 EPS.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The firm had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. During the same quarter in the previous year, the firm posted $0.19 earnings per share. The business’s revenue was up 41.6% on a year-over-year basis.

A number of other brokerages have also weighed in on INCY. Argus reaffirmed a “buy” rating and issued a $150.00 price target on shares of Incyte in a research note on Wednesday, September 13th. Royal Bank of Canada assumed coverage on shares of Incyte in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $136.00 price target on the stock. BMO Capital Markets cut their price target on shares of Incyte from $163.00 to $162.00 and set an “outperform” rating on the stock in a research note on Thursday, October 26th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Incyte in a research note on Wednesday, October 25th. Finally, Goldman Sachs Group assumed coverage on shares of Incyte in a research note on Friday, October 6th. They issued a “buy” rating and a $160.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $143.11.

Shares of Incyte (INCY) traded down $4.52 on Monday, reaching $96.29. 2,639,800 shares of the company’s stock were exchanged, compared to its average volume of 1,721,233. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82. Incyte has a 1 year low of $92.91 and a 1 year high of $153.15. The company has a market capitalization of $20,320.00, a price-to-earnings ratio of -120.36 and a beta of 0.74.

In related news, Director Paul A. Friedman sold 28,507 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $105.24, for a total transaction of $3,000,076.68. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Vijay K. Iyengar sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $97.26, for a total transaction of $486,300.00. The disclosure for this sale can be found here. Insiders sold 44,878 shares of company stock worth $4,636,494 over the last quarter. 17.70% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Nordea Investment Management AB increased its holdings in Incyte by 0.8% during the second quarter. Nordea Investment Management AB now owns 8,179 shares of the biopharmaceutical company’s stock worth $1,030,000 after buying an additional 67 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Incyte by 13.8% during the second quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 108 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in Incyte by 1.9% during the second quarter. Ameritas Investment Partners Inc. now owns 7,571 shares of the biopharmaceutical company’s stock worth $953,000 after buying an additional 143 shares during the last quarter. Symphony Asset Management LLC increased its holdings in Incyte by 20.1% during the second quarter. Symphony Asset Management LLC now owns 1,867 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 312 shares during the last quarter. Finally, Norinchukin Bank The increased its holdings in Incyte by 3.0% during the second quarter. Norinchukin Bank The now owns 11,795 shares of the biopharmaceutical company’s stock worth $1,485,000 after buying an additional 348 shares during the last quarter. Institutional investors and hedge funds own 90.74% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2018/01/10/incyte-co-expected-to-earn-q1-2018-earnings-of-0-33-per-share-incy.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit